Sipagladenant (Compound I) is an orally active adenosine receptor A2A inverse agonist. Sipagladenant can be used in frontal lobe dysfunction research . In Vivo Sipagladenant (oral administration; 0.3 mg/kg; once) treatment improves cognitive impairment due to a decline in dopamine function in the medial prefrontal cortex. Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve alternation behavior. Sipagladenant (oral administration; 0.1 mg/kg; once) treatment can improve gait parameters. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Medial prefrontal dopaminerjic terminal-lesioned CD(SD) IGS male ratDosage: 0.3 mg/kg Administration: Oral administration; 0.3 mg/kg; once Result: Showed longer exploration time of the novel object (65.03%) than that of the familiar object (34.97%) (p Form:Solid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Sipagladenant
CAS number：858979-50-7 molecular formula：C20H19N3O4S
overview
compound introduction
Specs
| Chinese alias | 西帕拉德南特 | ||
| English alias | - | ||
| CAS number | 858979-50-7 | molecular formula | C20H19N3O4S |
| molecular weight | 397.45 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
